SuperworthBioAge Labs price to book ratio BIOA
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 0.6×
- Peer median
- 2.2×
BioAge Labs' price to book ratio is 0.6× as of Oct 23, 2026.
The median for 10 large drugmakers of a similar size is 2.2×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.6× | 0.6× | 3.0× |
| 2025 | 1.8× | 0.4× | 1.8× |
| 2024 | 0.6× | 0.5× | 2.5× |
Against its peers
Companies in Drug Manufacturers - General nearest BioAge Labs' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| BIOABioAge Labs | 0.6× |
| NATRNatures Sunshine Products | 1.3× |
| ARVNArvinas | 0.8× |
| PBYIPuma Biotechnology | 4.1× |
| IRWDIronwood Pharmaceuticals | n/m |
| ZVRAZevra Therapeutics | 2.7× |
| CRMDCorMedix | 1.3× |
| LFVNLifevantage | 2.2× |
| COLLCollegium Pharmaceutical | 2.4× |
| ABUSArbutus Biopharma | 3.2× |
| SPROSpero Therapeutics | 1.5× |
| Peer median | 2.2× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on BioAge Labs
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.